ArticleInternational urology and nephrology2026
Global, regional, and national burdens of bladder cancer in individuals aged 60 years and older from 1990 to 2021: a cross-sectional study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBladder cancer (BC) is a leading global malignancy, disproportionately affecting older adults. However, comprehensive studies on its epidemiological burden specifically in this age group remain limited.
methodsUsing data from the Global Burden of Disease (GBD) 2021, we analyzed BC incidence, prevalence, mortality, and disability-adjusted life years (DALYs) among adults aged ≥ 60 years from 1990 to 2021. We employed joinpoint regression to identify temporal trend changes, decomposition analysis to quantify drivers of burden, and age-period-cohort modeling to distinguish the effects of age, time period, and birth cohort. Frontier analysis was used to benchmark performance relative to sociodemographic development, and we forecasted burden up to 2050 using GBD ensemble models. All analyses were conducted using R software (v4.2.3).
resultsFrom 1990 to 2021, global geriatric BC cases increased approximately 1.4-fold, driven by population growth and aging; age-standardized prevalence rate (ASPR) rose from 196 to 211 per 100,000, while incidence (ASIR), mortality (ASMR), and DALY rates (ASDALYs) declined slightly. Projections to 2050 indicate a near doubling of prevalent cases (~ 4.54 million) alongside continued declines in ASIR, ASMR, and ASDALYs. In 2021, high-SDI regions (e.g., North America, Western Europe) had the highest burden, whereas Oceania had the lowest. ASPR and ASIR correlated positively with SDI until ~ 0.8; ASMR and ASDALYs peaked around SDI 0.78 before declining. EAPCs for all metrics rose, then fell with SDI, decreasing significantly beyond ~ 0.72. Sex-based disparities widened, and socioeconomic gaps persisted. Higher-SDI countries showed greater potential for reducing BC burden in older adults.
conclusionsThis comprehensive analysis reveals a complex global landscape: successful control of age-standardized BC rates in the elderly is being counteracted by population growth and aging, leading to rising absolute burdens. The significant and growing disparities by sex, region, and SDI level highlight an urgent need for targeted, equitable policy interventions. Future health system planning must account for the escalating number of older BC patients, requiring integrated prevention and sustainable care models to manage this challenge.
Indexed as
Identifiers
41364142What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.